picropodophyllin has been researched along with Bone Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, JJ; Miao, SW; Wang, BJ; Wu, YT | 1 |
| Wan, Y | 1 |
| Choy, E; Duan, Z; Harmon, D; Hornicek, FJ; Mankin, H; Ryu, K; Schwab, J; Yang, C | 1 |
| Axelson, M; Coulton, L; Croucher, P; De Leenheer, E; De Raeve, H; Gallagher, O; Jernberg-Wiklund, H; Larsson, O; Menu, E; Nilsson, K; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K | 1 |
1 review(s) available for picropodophyllin and Bone Cancer
| Article | Year |
|---|---|
New Mechanism of Bone Cancer Pain: Tumor Tissue-Derived Endogenous Formaldehyde Induced Bone Cancer Pain via TRPV1 Activation.
Topics: Animals; Bone Neoplasms; Cancer Pain; Capsaicin; Cells, Cultured; Formaldehyde; Glycine Hydroxymethyltransferase; Histone Demethylases; Humans; Insulin-Like Growth Factor I; Mammary Neoplasms, Experimental; Neoplasm Proteins; Osteoblasts; Peripheral Nerves; Podophyllotoxin; Protein Kinase Inhibitors; Signal Transduction; TRPV Cation Channels | 2016 |
3 other study(ies) available for picropodophyllin and Bone Cancer
| Article | Year |
|---|---|
Picropodophyllin inhibits the growth of Ewing's sarcoma cells through the insulin‑like growth factor‑1 receptor/Akt signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Phosphorylation; Podophyllotoxin; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Sarcoma, Ewing; Signal Transduction | 2015 |
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Osteosarcoma; Podophyllotoxin; Protein Kinase Inhibitors; Receptor, IGF Type 1; RNA, Small Interfering | 2009 |
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Disease Models, Animal; Kaplan-Meier Estimate; Mice; Multiple Myeloma; Neovascularization, Pathologic; Podophyllotoxin; Receptor, IGF Type 1 | 2007 |